Written question asked by Rupert Lowe (Restore Britain) on Friday, 10 July 2026, in the House of Commons. It was due for an answer on Tuesday, 14 July 2026. It was answered by James Frith (Labour) on Tuesday, 18 August 2026 on behalf of the Department of Health and Social Care.
Semaglutide
- Question
-
To ask the Secretary of State for Health and Social Care, whether his Department has independently assessed the clinical benefits and effectiveness of Wegovy.
- Answer
-
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new licensed medicines represent a clinically and cost-effective use of resources.
Semaglutide (Wegovy) is recommended by NICE for both managing overweight and obesity and reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity.
Secondary information
- Type
- Written question
- Reference
- 17866
- Session
- 2026-27
- Subjects
- Research Obesity Semaglutide
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-08-18 12:45:29 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/17866
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/17866
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2026-27/17866